Publications

Antimicrobial Activity of Dalbavancin against Gram-Positive Bacteria Isolated from Patients with Bone and Joint Infections from the United States (US) and Europe (2016-2020): Results from the International Dalbavancin Evaluation of Activity (IDEA) Program. Lead author: HS Sader presented at IDWeek 2021, September 29-October 3, Virtual Conference

In vitro Activity of Tebipenem against a Recent Collection of Fastidious Organisms Recovered from Respiratory Tract Infections. Lead author: SJR Arends presented at IDWeek 2021, September 29-October 3, Virtual Conference

Five-Year Trends on the Susceptibility of Enterobacterales to Plazomicin and Other Aminoglycosides in Hospitals in the United States (2016-2020). Lead author: HS Sader presented at IDWeek 2021, September 29-October 3, Virtual Conference

Antimicrobial Activity of Dalbavancin against Gram-Positive Bacteria Isolated from Patients Hospitalized with Bacteremia in United States and European Medical Centers: Results from the International Dalbavancin Evaluation of Activity (IDEA) Program (2018-2020). Lead author: HS Sader presented at IDWeek 2021, September 29-October 3, Virtual Conference

The β-Lactamase Inhibitor QPX7728 Restores the Activity of β-Lactam Agents against Contemporary ESBL-Producing and CRE Isolates, Including Isolates Producing Metallo-β-Lactamases. Lead author: J Lindley presented at IDWeek 2021, September 29-October 3, Virtual Conference

Comparative Activity of Meropenem-Vaborbactam and Ceftazidime-Avibactam Against Multidrug-Resistant Enterobacter cloacae from Hospitals in Europe and United States. Lead author: M Castanheira presented at IDWeek 2021, September 29-October 3, Virtual Conference

Antimicrobial Activity of Ceftibuten-Avibactam against Clinical Isolates of Enterobacterales Producing Clinically Relevant Beta-Lactamases. Lead author: HS SAder presented at IDWeek 2021, September 29-October 3, Virtual Conference

In vitro Activity of Exebacase (CF-301) against Staphylococcus aureus Causing Bacteremia in the United States, Including Multidrug-Resistant Subsets. Lead author: RE Mendes presented at IDWeek 2021, September 29-October 3, Virtual Conference

In vitro Activity of Gepotidacin against Escherichia coli Causing Urinary Tract Infections in the United States, Including Molecularly Characterized, Fluoroquinolone-Resistant Subsets. Lead author: RE Mendes presented at IDWeek 2021, September 29-October 3, Virtual Conference

Ceftobiprole Activity against Drug-Resistant Staphylococcus aureus Clinical Isolates Collected in the United States from 2016 through 2020. Lead author: LR Duncan presented at IDWeek 2021 September 29-October 3, Virtual Conference

Antimicrobial Activity of Ceftaroline and Comparator Agents against Ceftriaxone-Nonsusceptible Streptococcus pneumoniae from the United States (2008-2020). Lead author: HS Sader presented at IDWeek 2021, September 29-October 3, Virtual Conference

In Vitro Activity of Lefamulin against Staphylococcus aureus Isolated from the Lower Respiratory Tract of Children with Cystic Fibrosis. Lead author: HS Sader presented at IDWeek 2021, September 29-October 3, Virtual Conference

In Vitro Activity of Cefiderocol and Comparator Agents against Molecularly Characterized Carbapenem-resistant Enterobacterales Clinical Isolates Causing Infection in United States Hospitals (2020). Lead author: RE Mendes presented at IDWeek 2021, September 29-October 3, Virtual Conference

In vitro Activity of Tebipenem against Relevant Clinical Isolates in the Presence of Pulmonary Surfactant. Lead author: SJR Arends presented at IDWeek 2021, September 29-October 3, Virtual Conference

Cefiderocol In Vitro Activity against Molecularly Characterized Acinetobcter baumannii-calcoaceticus Complex and Pseudomonas aeruginosa Clinical Isolates Causing Infection in United States Hospitals (2020). Lead author: RE Mendes presented at IDWeek 2021, September 29-October 3, Virtual Conference

Activity of Meropenem-Vaborbactam and Comparator Agents against Carbapenemase-Negative, Carbapenem-Resistant Enterobacterales from US Hospitals. Lead author: M Castanheira presented at IDWeek 2021, September 29-October 3, Virtual Conference

Tebipenem In Vitro Activity against a Collection of Pathogens Responsible for Urinary Tract Infections in the US. Lead author: RE Mendes presented at IDWeek 2021, September 29-October 3, Virtual Conference

Activity of Cefiderocol and Comparators against Gram-Negative Isolates from US Patients Hospitalized with Pneumonia. Lead author: D Shortridge presented at IDWeek 2021, September 29-October 3, Virtual Conference

Antimicrobial Activity of Aztreonam-Avibactam and Comparator Agents against Gram-Negative Bacteria Isolated from Bloodstream and Complicated Urinary Tract Infections in Europe, Asia, and Latin America (2019-2020). Lead author: HS Sader presented at IDWeek 2021, September 29-October 3, Virtual Conference

Activity of Rezafungin and Comparator Antifungal Agents Tested Against a Worldwide Collection of Contemporaneous Invasive Fungal Isolates (2019-2020). Lead author: CG Carvalhaes presented at IDWeek 2021, September 29-October 3, Virtual Conference

Epidemiology and Susceptibility Profiles of ST131-025b Escherichia coli Detected Among Cephalosporin- and/or Carbapenem-Resistant Isolates Collected in United States Hospitals. Lead author: M Castanheira presented at IDWeek 2021, September 29-October 3, Virtual Conference

Occurrence of β-Lactamases among Enterobacterales Isolated from United States Hospitals: Results of the INFORM Surveillance Program for Ceftazidime-Avibactam. Lead author: M Castanheira presented at IDWeek 2021, September 29-October 3, Virtual Conference

In Vitro Analysis of AmpC β-lactamase Induction by Tebipenem in Enterobacterales and Pseudomonas aeruginosa. Lead author: RE Mendes presented at IDWeek 2021, September 29-October 3, Virtual Conference

Optimization of a 96-Well Plate Format Assay to Evaluate Concentration-Dependent Activity of a Monoclonal Antibody against the O Antigen 025b from ST131-H30 Escherichia coli. Lead author: J Lindley presented at IDWeek 2021, September 29-October 3, Virtual Conference

In vitro Activity of Tebipenem, an Orally Available Carbapenem Agent, against a Collection of Surveillance Gram-positive Clinical Isolates. Lead author: SJR Arends presented at IDWeek 2021, September 29-October 3, Virtual Conference

Analysis of Resistance to Oral Standard of Care Antibiotics for Urinary Tract Infections Caused by Escherichia coli and Staphylococcus saprophyticus Collected Worldwide between 2019-2020. Lead author: SJR Arends presented at IDWeek 2021, September 29-October 3, Virtual Conference

Update on the In Vitro Activity of Ceftaroline against Staphylococcus aureus from United States (US) Medical Centers Stratified by Infection Type (2018-2020). Lead author: HS Sader presented at IDWeek 2021, September 29-October 3, Virtual Conference

Molecular Epidemiology of Escherichia coli Causing Urinary Tract Infections in United States and In Vitro Activity of Tebipenem, Including against Strain Lineage and Resistant Subsets (2018-2020). Lead author: RE Mendes presented at IDWeek 2021, September 29-October 3, Virtual Conference

Antimicrobial Activity of Plazomicin against Multidrug-resistant Enterobacterales: Results from 3 Years of Surveillance in Hospitals in the United States (2018-2020). Lead author: HS Sader presented at IDWeek 2021, September 29-Ocrtober 3, Virtual Conference

Oritavancin Activity Against Methicillin-Resistant S. aureus (MRSA) Isolates Causing Skin and Skin Structure Infections in US Hospitals (2017-2019). Lead author: CG Carvalhaes presented at IDWeek 2021, September 29-October 3, Virtual Conference

Minocycline activity against Acinetobacter baumannii-calcoaceticus species complex, Burkholderia cepacia complex, and Stenotrophomonas maltophilia from US hospitals. Lead author: D Shortridge, presented at IDWeek 2021, September 29-October 3, Virtual Conferece